Featured Press Release

  • Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
    8/7/18 6:50 am EDT

    -- Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three and six months ended June 30, 2018. Highlights of and subsequent to the second quarter of 2018 include: Business and Recent Highlights: EHS clinical trial for RYANODEX® will be conducted August 20 – 24, 2018 during the Hajj pilgrimage; Eagle received a favorable decision bySee More
  • Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018
    7/25/18 7:00 am EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or “the Company”) (Nasdaq: EGRX) today announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as followsSee More
  • FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
    7/9/18 7:00 am EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. As a result, and consistent with the order issued bySee More

Featured Presentation

Business Wire InvestorHQsm